The effects of aldose reductase inhibitor on the corneal endothelial morphology in diabetic rats.
Diabetic rats were produced by intravenous injection of streptozotocin. Of these, eleven rats were treated with topical instillation of 0.5% aldose reductase inhibitor (ARI), while ten received vehicle alone. The corneal endothelium of these diabetic rats was examined by specular microscopy and compared to age-matched nondiabetic rats (ten rats). Computerized morphometric analysis of individual cells demonstrated that the endothelium of the untreated diabetic rats had marked polymegathism (increased coefficient of variation in cell area) and pleomorphism (decreased percentage of hexagonal cells), as previously observed in diabetic patients. Similar endothelial changes were also noted in the ARI-treated diabetic rats, but to a significantly lesser extent. These results suggest that topically applied ARI can be effective in reducing morphologic changes of the diabetic endothelium, and that activation of the sorbitol pathway may be implicated in the etiology of such endothelial changes.
D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors*; D000818:Animals; D001835:Body Weight; D002452:Cell Count; D003315:Cornea / Q000473:pathology*; D003921:Diabetes Mellitus, Experimental / Q000473:pathology*; D004727:Endothelium / Q000473:pathology; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D013311:Streptozocin; D013401:Sugar Alcohol Dehydrogenases / Q000037:antagonists & inhibitors*
D013311:Streptozocin; D013401:Sugar Alcohol Dehydrogenases; D000449:Aldehyde Reductase